Hainan Poly Pharm. Co., Ltd

SZSE:300630 Stock Report

Market Cap: CN¥4.7b

Hainan Poly Pharm Valuation

Is 300630 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300630 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 300630's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 300630's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300630?

Other financial metrics that can be useful for relative valuation.

300630 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.5x
Enterprise Value/EBITDA62.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 300630's PS Ratio compare to its peers?

The above table shows the PS ratio for 300630 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.9x
002437 HARBIN GLORIA PHARMACEUTICALS
2xn/aCN¥4.9b
600851 Shanghai Haixin Group
7.4xn/aCN¥5.4b
300147 Xiangxue PharmaceuticalLtd
2.6xn/aCN¥4.8b
301393 Suzhou Highfine Biotech
11.7xn/aCN¥4.7b
300630 Hainan Poly Pharm
3.7xn/aCN¥4.7b

Price-To-Sales vs Peers: 300630 is good value based on its Price-To-Sales Ratio (3.7x) compared to the peer average (5.9x).


Price to Earnings Ratio vs Industry

How does 300630's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.4%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.4%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 300630 is expensive based on its Price-To-Sales Ratio (3.7x) compared to the CN Pharmaceuticals industry average (3.4x).


Price to Sales Ratio vs Fair Ratio

What is 300630's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300630 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 300630's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies